What Managed Care Needs to Know About Recent Real-World Evidence and Best Practices for CDK 4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: Utilizing Recent Data for Optimal Decision Making

A continuing medical education activity provided by NAMCP and AAMCN

This is Part 2 of the series focusing on Management of HR+/HER2- Metastatic Breast Cancer.

This activity is an archive from the webinar held December 17, 2021.

This activity is valid from January 1, 2022, to January 1, 2024.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2021. The incidence in women in the United States is 1 in 8 (about 13 percent). About 43,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely, and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with HR+/HER2- advanced breast cancer, several new agents, including CDK 4/6 inhibitors, have changed the paradigm in the last 10 years, and recent real-world data has been released that shows the strong efficacy and safety of these options. This webinar series will provide managed care professionals and oncologists with the latest real-world data and strategies in the evolving treatment paradigm. Participants will leave with ability to understand and utilize recent real world and clinical trial data, implement best strategies, tackle first line treatment decisions, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve access and outcomes in patients with HR+/HER2- metastatic breast cancer.

Upon completion of this activity, participants will be able to:

  • Examine the unmet economic needs in HR+/HER2- metastatic breast cancer and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity

  • Explore real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer

  • Formulate recommendations to ensure appropriate access for first-line treatment of HR+/HER2-metastatic breast cancer with CDK 4/6 inhibitors

  • Assess the managed care considerations of CDK 4/6 inhibitors by exploring where these agents fit into current metastatic breast cancer management paradigm

  • Transform therapeutic advances and resource utilization data on emerging therapies in alopecia areata into informed health plan decisions and formulary discussions


Faculty: Gary Owens, MD
Gary Owens Associates


Dr. Owens has served as a consultant for Sanofi/Regeneron, ICON, Octave Biosciences, Noctrix Inc, Magnolia Innovations, Princeton Biosciences, MCRA, and Payer Sciences.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue